You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Revolution Medicines reported $197.6 million in RAS on Q net product revenue during the quarter, with more than 5,000 patients treated during five weeks of commercialization. It ended the quarter with $3.7 billion in cash, cash equivalents, and marketable securities.
Revolution Medicines began selling RASONQUE after FDA approval in August 2026, generating $197.6 million in net product revenue for the three and nine months ended September 30, 2026. Revenue included initial channel stocking.
Revolution Medicines reported $197.6 million in RASONQUE net product revenue for the quarter ended September 30, 2026. Cash totaled $3.7 billion, net loss was $407.5 million, and a positive CHMP opinion advanced possible European Union approval.
Following FDA approval of RASONQUE™ (daraxonrasib), Revolution Medicines, Inc. borrowed a $250.0 million Tranche A Loan, paid a $5.0 million draw fee, and declined a potential $250.0 million Tranche 3 payment.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| aggregate principal amount of 0.50% convertible senior notes due 2033 issued | $500M | April 2026 | — |
| committed, flexible capital remaining under Royalty Pharma funding arrangements | 1.5B | Q2 2026 | — |
| confirmed overall response rate (ORR) for elironrasib plus standard of care in first-line RAS G1 | 85% | Q2 2026 data cutoff May 11, 2026 | — |
| disease control rate (DCR) for elironrasib plus standard of care in first-line RAS G12C NSCLC | 97% | Q2 2026 data cutoff May 11, 2026 | — |
| disease control rate (DCR) for zoldonrasib plus standard of care in first-line RAS G12D NSCLC | 100% | Q2 2026 data cutoff May 11, 2026 | — |
| efficacy evaluable patients in zoldonrasib plus standard of care NSCLC combination analysis | 28 | Q2 2026 data cutoff May 11, 2026 | — |
| gross proceeds from April 2026 concurrent public offerings | $2.23B | April 2026 | — |
| non-cash charge related to change in fair value of EQRx warrants | $151M | Q2 2026 | — |
| overall response rate (ORR) for zoldonrasib plus standard of care in first-line RAS G12D NSCLC | 82% | Q2 2026 data cutoff May 11, 2026 | — |
| patients analyzed in zoldonrasib plus standard of care NSCLC combination analysis | 38 | Q2 2026 data cutoff May 11, 2026 | — |
| patients receiving daraxonrasib through Expanded Access Program | 2,000 | since opening of the Expanded Access Program through Q2 2026 | — |
| progression-free rate at 6 months for elironrasib plus standard of care in first-line RAS G12C N | 95% | Q2 2026 data cutoff May 11, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVMD
this stock
Revolution Medicines, Inc.
|
$37.27B | +116.3% | — | — | 6.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Revolution Medicines began selling RASONQUE after FDA approval in August 2026, generating $197.6 million in net product revenue for the three and nine months ended September 30, 2026. Revenue included initial channel stocking.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVMD | -10.4% | -3.2% | +11.2% | -9.9% | +116.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -13.0% | -2.0% | +10.7% | -9.8% | +105.7% |
